US regulators gave the green light to Autolus Therapeutics’ cell therapy for adult B-cell precursor acute lymphoblastic leukemia, or B-ALL, that has returned or is not responding to prior treatment ...

The FDA this week posted an untitled letter sent Oct. 17 to China-based active pharmaceutical ingredient (API) manufacturer ...

Alan Bash is joining Legend Biotech as its president of Carvykti, an unconventional, newly-created role to oversee the ...

Nkarta is punting development of a natural killer cell therapy in cancer to focus instead on the same candidate's prospects ...

Eisai has slashed Leqembi's sales forecast by 25% this year, lowering the ceiling for one of the industry's most ...

Gilead said its Covid-19 antiviral Veklury had $692 million in third-quarter sales, far more than the $270 million Wall ...

Athira Pharma has shelved a daily drug for Alzheimer’s after a mid-stage flop, instead shifting its focus to an oral ...

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

California voters supported a state ballot measure on Tuesday that would increase oversight around the 340B federal drug ...

Pfizer is doubling down on its commitment to China as the company continues to face activist pressure around its plans for a ...

In another sign that biopharma companies are slowing their early R&D efforts, Charles River Laboratories is shuttering more than a dozen sites. The service provider is working on “consolidating ...

GSK is leaving the biopharma trade group BIO, a spokesperson confirmed, the latest large pharma to back out of the group. “​​At this time, we believe there are other areas ...